Hold Natco Pharma; Target Of Rs 595: ICICI Direct

Revenues de-grew 40.6% YoY to Rs 455.7 crore (I-direct estimate: Rs 541.5 crore) on the back of high base of gOseltamivir (flu) in the US. EBITDA margins were at 32.5% against 49.9% in Q4FY18 (I-direct estimate: 33.4%) mainly due to high base of gOseltamivir (flu) in the US. EBITDA de-grew 61.3% YoY to Rs 148.3 crore against I-direct estimates of Rs180.9 crore. Net profit de-grew 59.7% YoY to Rs120.8 crore (I-direct estimates: Rs134.4 crore). – Money Control